BioSpherix celebrates Grand Opening of the Center for Cytocentric Technology (CCT) in Parish, New York

PARISH, N.Y. – May 18, 2026: BioSpherix officially celebrated the grand opening of its new Center for Cytocentric Technology (CCT) facility today with a ribbon-cutting ceremony attended by regional leaders in biotechnology, manufacturing, economic development, academia, and government.

Located at 25 Union Street in Parish, New York, the new GMP-level CDMO/CRO facility was established to help accelerate cell and gene therapy development while strengthening New York State’s growing life sciences ecosystem.

BioSpherix, a New York-based biotechnology company, is a global leader in the development of advanced closed-system technologies that create physiologically optimized environments for cell culture, bioprocessing, and regenerative medicine applications. The company’s Cytocentric® approach focuses on maintaining precise environmental control around living cells to improve consistency, reproducibility, and translational relevance across research and manufacturing workflows.

The Center for Cytocentric Technology expands that mission by providing infrastructure, expertise, and scalable capabilities for both startup and established biotechnology organizations across the region.

“Cell and gene therapy development is evolving rapidly, and there is a growing need for modular, flexible infrastructure that can adapt alongside the science,” said Ahmed Mustafa, CEO of BioSpherix. “CCT was designed to provide companies and researchers with access to scalable, physiologically controlled systems that support everything from early-stage process development through GMP-aligned manufacturing. As demand for advanced therapies continues to grow, facilities like this will play an increasingly important role in helping accelerate innovation while strengthening New York’s life sciences ecosystem.”

The launch comes at a pivotal time for the biotechnology industry as demand for cell and gene therapies continues to rise alongside increased public and private investment in regenerative medicine, biomanufacturing, and advanced therapeutics. New York State has also identified cell and gene therapy as a strategic growth sector, creating new opportunities for regional collaboration, workforce development, and scientific innovation.

By establishing the facility in Central New York, BioSpherix aims to help expand access to advanced biotechnology infrastructure in an area historically underserved by large-scale life sciences investment.

In addition to supporting therapeutic development programs, CCT is expected to play an important role in workforce training and education by helping equip the next generation of scientists, engineers, and biomanufacturing professionals with hands-on experience in advanced cell culture and manufacturing technologies.

Guests attending the grand opening participated in formal remarks, the official ribbon-cutting ceremony, and guided tours of the facility showcasing BioSpherix’s fully closed, environmentally controlled systems designed to help mitigate contamination risks and reduce variability in sensitive cell-based workflows.

The opening of CCT reflects BioSpherix’s broader commitment to advancing regenerative medicine innovation while building stronger partnerships across industry, academia, healthcare, and government throughout New York State and beyond.

For more information about BioSpherix and the Center for Cytocentric Technology, visit BioSpherix.

Media Contact:

Madeleine Keefe, Marketing Manager
mkeefe@biospherix.com